$190.27
+0.82%Oct 23, 2026, 11:30 UTC
Revolution Medicines, Inc. announced exploratory subgroup analyses from the Phase 3 RASolute 302 trial showing that RASONQUE (daraxonrasib) provided an overall survival benefit versus chemotherapy across evaluated RAS genotype subgroups in previously treated metastatic pancreatic cancer.
Source:Oct 21, 2026, 20:05 UTC
Revolution Medicines announced that it will report financial results for the third quarter of 2026 after market close on November 4, 2026.
Source:Oct 20, 2026, 12:00 UTC
Revolution Medicines, Inc. began treating patients in the Phase 3 RASolve 308 trial evaluating zoldonrasib with pembrolizumab and chemotherapy as first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer.
Oct 15, 2026, 13:45 UTC
The EUROPEAN MEDICINES AGENCY’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
Oct 5, 2026, 12:00 UTC
Revolution Medicines, Inc. began treating patients in the Phase 3 RASolute 309 trial evaluating RASONQUE (daraxonrasib) plus zoldonrasib as first-line treatment for metastatic RAS G12D pancreatic adenocarcinoma.
Source:Sep 21, 2026, 08:30 UTC
In late August 2026, the U.S. Food and Drug Administration approved daraxonrasib, a new KRAS-targeting therapeutic for previously treated pancreatic cancer developed by Revolution Medicines.
Source:Sep 14, 2026, 20:05 UTC
The U.S. FDA granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel for treatment-naïve metastatic pancreatic adenocarcinoma.
Source:Sep 5, 2026, 10:00 UTC
The FDA approved a pill from Revolution Medicines to treat late-stage prostate cancer.
Source:Sep 2, 2026, 21:50 UTC
Revolution Medicines announced that The New England Journal of Medicine published Phase 1/2 clinical data on its drug RASONQUE (daraxonrasib) for metastatic non-small cell lung cancer.
Sep 1, 2026, 10:17 UTC
Revolution Medicines, Inc. signed four lease agreements for buildings at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, with staggered commencements from September 26, 2027 to September 1, 2028 and initial terms ending September 2042, subject to Phase II Closing by the landlords' acquisition of the properties.
Aug 28, 2026, 17:15 UTC
Revolution Medicines' drug daraxonrasib (brand name Rasonque) was approved by the FDA this week for treating pancreatic cancer with a key mutation.
Aug 10, 2026, 10:00 UTC
BeOne Medicines and Revolution Medicines announced a multi-part collaboration including clinical development and regional commercialization of drug combinations.
Aug 5, 2026, 23:00 UTC
Revolution Medicines, Inc. held its Q2 2026 earnings call on August 5, 2026.
Source:Jun 24, 2026, 15:16 UTC
Revolution Medicines starts a Phase III clinical trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer with RAS G12D mutations.
Source: